Biogen (NASDAQ:BIIB) Upgraded to "Buy" at Argus

Key Points

• Argus upgraded Biogen to “Buy” from “Hold” and set a $280 price target, implying approximately 14.7% upside from the reported share price.
• Biogen exceeded quarterly expectations, reporting $2.62 in adjusted EPS versus a $1.99 consensus estimate and $2.80 billion in revenue, up 10.6% year over year.
• Analyst sentiment is broadly positive, with a “Moderate Buy” consensus rating and average price target of $246.79, although Biogen posted a GAAP loss largely due to transaction-related expenses.

Biogen (NASDAQ:BIIB - Get Free Report) was upgraded by research analysts at Argus from a "hold" rating to a "buy" rating in a report released on Thursday, MarketBeat Ratings reports. The brokerage presently has a $280.00 price target on the biotechnology company's stock. Argus's price target would indicate a potential upside of 14.73% from the company's current price.

A number of other research analysts have also recently commented on BIIB. Barclays boosted their target price on shares of Biogen from $200.00 to $230.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Wall Street Zen lowered shares of Biogen from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. TD Cowen lifted their price target on shares of Biogen from $225.00 to $250.00 and gave the stock a "buy" rating in a research note on Wednesday, October 21st. Stifel Nicolaus set a $242.00 price objective on shares of Biogen in a report on Thursday, September 10th. Finally, Citigroup reissued a "neutral" rating on shares of Biogen in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $246.79.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $244.05 on Thursday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. Biogen has a 1-year low of $138.00 and a 1-year high of $258.78. The company has a market capitalization of $36.06 billion, a price-to-earnings ratio of 43.19, a PEG ratio of 2.99 and a beta of 0.09. The business has a 50-day moving average of $225.73 and a 200-day moving average of $200.39.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, beating the consensus estimate of $1.99 by $0.63. The business had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.63 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The company's revenue was up 10.6% on a year-over-year basis. During the same period last year, the business posted $4.81 EPS. On average, equities analysts anticipate that Biogen will post 12.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Biogen during the third quarter valued at $15,444,000. Profund Advisors LLC grew its holdings in shares of Biogen by 38.7% in the 3rd quarter. Profund Advisors LLC now owns 11,876 shares of the biotechnology company's stock worth $2,683,000 after purchasing an additional 3,316 shares during the last quarter. ProShare Advisors LLC grew its holdings in shares of Biogen by 1.5% in the 3rd quarter. ProShare Advisors LLC now owns 35,671 shares of the biotechnology company's stock worth $8,057,000 after purchasing an additional 544 shares during the last quarter. Vise Technologies Inc. grew its holdings in shares of Biogen by 14.7% in the 3rd quarter. Vise Technologies Inc. now owns 7,601 shares of the biotechnology company's stock worth $1,717,000 after purchasing an additional 974 shares during the last quarter. Finally, Grandfield & Dodd LLC acquired a new stake in shares of Biogen during the 3rd quarter worth about $206,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported adjusted third-quarter earnings of $2.62 per share, well above analyst expectations of roughly $1.99–$2.06, while revenue rose 10.6% year over year to $2.80 billion, also exceeding estimates. Biogen third-quarter earnings report
• Positive Sentiment: The newer growth portfolio continued to offset pressure on older multiple sclerosis products, with revenue increasing 49% to $1.26 billion. Rare-disease revenue rose 27% to $676 million, helped in part by the first full quarter of products acquired through Apellis. Biogen Q3 revenue and earnings update
• Positive Sentiment: Biogen raised the lower end of its 2026 adjusted EPS guidance to $12.20, producing a new range of $12.20 to $13.00. Needham and Baird subsequently raised their price targets to $290 and assigned bullish “buy” and “outperform” ratings, respectively. Analyst forecasts for Biogen
• Neutral Sentiment: Biogen plans to present additional Alzheimer’s disease data at CTAD 2026, including long-term CELIA study data for diranersen and extended real-world and clinical evidence for lecanemab. The presentations could provide future pipeline catalysts, but the data will not affect near-term earnings. Biogen CTAD 2026 announcement
• Negative Sentiment: Despite the adjusted-profit beat, Biogen posted a GAAP net loss of $20.6 million, or $0.14 per share, compared with a profit of $466.5 million a year earlier. The loss primarily reflected transaction-related expenses, including $284 million of acquired research and development costs tied largely to the RayThera acquisition. Biogen GAAP loss report
• Negative Sentiment: Barclays raised its price target to $230 but retained an “equal weight” rating, leaving its target below the current trading level. Unusually heavy put-option activity also indicated increased near-term hedging or bearish speculation. Barclays Biogen rating

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company's portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer's disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.